Status:
COMPLETED
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily v...
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 3 months
- HbA1c between 7.5-11.0% on monotherapy or
- HbA1c between 7.0-10.0% on dual therapy
- BMI maximum 45 kg/m2
Exclusion
- Any clinically significant disease history in the opinion of the investigator
- Severe heart disease
- Pregnancy
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT00399711
Start Date
November 1 2006
End Date
November 1 2007
Last Update
February 10 2017
Active Locations (103)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Vestavia Hills, Alabama, United States, 35209
2
Novo Nordisk Investigational Site
Glendale, Arizona, United States, 85306
3
Novo Nordisk Investigational Site
Mesa, Arizona, United States, 85206
4
Novo Nordisk Investigational Site
Jonesboro, Arkansas, United States, 72401